Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer

Purpose Optimal care for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) requires coordination across multiple providers, creating substantial time toxicity—the time patients spend engaged with the health care system. This study quantified total time toxicity and identified predictors of prolonged time toxicity in patients with metastatic PDAC. Methods We retrospectively analyzed patients with metastatic PDAC treated at a high-volume center from 2018 to 2022, excluding those who did not receive cancer-directed therapy or received care at multiple facilities. Time toxicity was defined as the proportion of overall survival (OS) spent in cancer-related health care encounters, with hospice time excluded. Beta regression identified predictors of time toxicity, incorporating OS as a scaling factor. Secondary outcomes included systemic therapy in the last 30 days of life, hospice transition after hospitalization, and inpatient death. Results Among 177 patients (median age 66 years; 57.1% male; 81.9% White), the majority received chemotherapy (n = 175) and palliative care consultation (n = 107). Median total time toxicity was 20% (IQR, 15%-28%), including 7% inpatient (IQR, 3%-16%) and 10% ambulatory (IQR, 8%-13%). Overall, 39% (n = 69) received systemic therapy in the last 30 days of life, 42.4% (n = 75) transitioned to hospice after hospitalization, and 14.8% (n = 21) died inpatient. On multivariable analysis, older age, rural/urban residence, and chemotherapy regimen predicted time toxicity (all P < .05). Each additional year of age was associated with a reduced time toxicity of 0.29%; urban residence was associated with a 3.3% increase in time toxicity compared with rural; and receiving multiple chemotherapy regimens was associated with 8.65% decrease compared with 5-fluorouracil–based regimens only. Conclusion Patients with metastatic PDAC spend roughly 1 in 5 days of survival engaged in health care interactions. Demographic, socioeconomic, and treatment-related factors all influence time toxicity.

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2026-10-27
DOI
https://doi.org/10.1200/op-26-00413
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer

Aslam M. Ejaz, Patrick L. Quinn, McKenzie L. Schaefer
4 links
JCO Oncology Practice
Pancreatic and Hepatic Oncology Research
article

Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer

Aslam M. Ejaz, Patrick L. Quinn, McKenzie L. Schaefer
article en

Abstract

Purpose Optimal care for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) requires coordination across multiple providers, creating substantial time toxicity—the time patients spend engaged with the health care system. This study quantified total time toxicity and identified predictors of prolonged time toxicity in patients with metastatic PDAC. Methods We retrospectively analyzed patients with metastatic PDAC treated at a high-volume center from 2018 to 2022, excluding those who did not receive cancer-directed therapy or received care at multiple facilities. Time toxicity was defined as the proportion of overall survival (OS) spent in cancer-related health care encounters, with hospice time excluded. Beta regression identified predictors of time toxicity, incorporating OS as a scaling factor. Secondary outcomes included systemic therapy in the last 30 days of life, hospice transition after hospitalization, and inpatient death. Results Among 177 patients (median age 66 years; 57.1% male; 81.9% White), the majority received chemotherapy (n = 175) and palliative care consultation (n = 107). Median total time toxicity was 20% (IQR, 15%-28%), including 7% inpatient (IQR, 3%-16%) and 10% ambulatory (IQR, 8%-13%). Overall, 39% (n = 69) received systemic therapy in the last 30 days of life, 42.4% (n = 75) transitioned to hospice after hospitalization, and 14.8% (n = 21) died inpatient. On multivariable analysis, older age, rural/urban residence, and chemotherapy regimen predicted time toxicity (all P < .05). Each additional year of age was associated with a reduced time toxicity of 0.29%; urban residence was associated with a 3.3% increase in time toxicity compared with rural; and receiving multiple chemotherapy regimens was associated with 8.65% decrease compared with 5-fluorouracil–based regimens only. Conclusion Patients with metastatic PDAC spend roughly 1 in 5 days of survival engaged in health care interactions. Demographic, socioeconomic, and treatment-related factors all influence time toxicity.

JCO Oncology Practice
The Ohio State University Wexner Medical Center (US), University of Illinois Chicago (US), The Ohio State University (US)
Good health and well-being
Openalex Percentile: Top 16%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon